{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:10:57Z","timestamp":1790212257821,"version":"4.1.0"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>The open-label randomized phase 2 LACOG0415 trial evaluated 3 treatment strategies for patients with advanced castration-sensitive prostate cancer (CSPC): androgen deprivation therapy (ADT) plus abiraterone acetate and prednisone (AAP), apalutamide (APA) alone, or APA plus AAP.<\/jats:p><\/jats:sec>Objective<\/jats:title>To investigate the association of ADT plus AAP, APA alone, or APA plus AAP with health-related quality of life (HRQOL) in patients with advanced CSPC in the LACOG0415 trial.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>The LACOG0415 randomized clinical trial comprised 128 patients with advanced CSPC who were randomized (1:1:1) to 1 of 3 treatment arms from October 16, 2017, to April 23, 2019. Statistical analysis was conducted from March to September 2022.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Patients were randomized (1:1:1) to 1 of 3 treatment arms: ADT plus AAP, APA alone, or APA plus AAP.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Health-related quality of life was evaluated using the Functional Assessment of Cancer Therapy\u2013Prostate (FACT-P) questionnaire, including its subscales, completed at baseline and every 4 weeks until week 25. FACT-P scores range from 0 to 156, and higher scores indicate better HRQOL. Mean changes in score from baseline to week 25 were adjusted by baseline score and were calculated to evaluate whether there was a difference according to the treatment arm using a mixed-effect model for repeated measures. Time to deterioration was estimated by Kaplan-Meier curves and compared by stratified log-rank test. Analysis was performed on an intention-to-treat basis.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 128 patients with advanced CSPC were randomized to receive ADT plus AAP (n\u2009=\u200942; median age, 69.8 years [IQR, 58.9-71.6 years]), APA alone (n\u2009=\u200942; median age, 69.5 years [IQR, 59.8-72.6 years]), or APA plus AAP (n\u2009=\u200944; median age, 71.0 years [IQR, 63.0-72.3 years]). Metastatic disease was present in 95 patients (74.2%), high-risk biochemical recurrence disease in 22 (17.2%), and locally advanced disease in 11 (8.6%). There was no significant difference in baseline mean (SD) FACT-P total scores and subscales among the 3 treatment arms (FACT-P total score: ADT plus AAP arm, 118.5 [24.3]; APA alone arm, 116.1 [23.9]; AAP plus APA arm, 114.9 [18.1]; P<\/jats:italic>\u2009=\u2009.69). Health-related quality of life was maintained during treatment period, and there were no statistically significant differences at 25 weeks in mean (SD) FACT-P total scores or subscales between treatment arms (FACT-P total score: ADT plus AAP arm, 122.3 [20.4]; APA alone arm, 119.5 [16.4]; AAP plus APA arm, 119.9 [20.3]). The APA alone and AAP plus APA arms were not associated with meaningful improvements in HRQOL compared with the ADT plus AAP arm, except in time to deterioration of the emotional well-being score, which was more favorable in the APA alone arm (reference arm: ADT plus AAP arm; APA alone arm: hazard ratio, 0.37 [0.15-0.85]; P<\/jats:italic>\u2009=\u2009.02; ADT plus AAP arm: hazard ratio, 0.56 [0.26-1.19]; P<\/jats:italic>\u2009=\u2009.13). Limitations include short follow-up period and the absence of other questionnaires to capture differences between therapies.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this prespecified secondary analysis of a randomized clinical trial of ADT plus AAP, APA alone, or APA plus AAP for patients with advanced CSPC, HRQOL was not statistically different between treatments with APA alone or APA plus AAP as compared with ADT plus AAP. Larger studies with longer follow-up and more specific questionnaires are needed to further evaluate HRQOL with these treatment strategies.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT02867020<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.54253","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T16:01:25Z","timestamp":1736784085000},"page":"e2454253","source":"Crossref","is-referenced-by-count":5,"title":["Androgen Receptor Pathway Inhibitor Therapy for Advanced Prostate Cancer"],"prefix":"10.1001","volume":"8","author":[{"given":"Diogo Assed","family":"Bastos","sequence":"first","affiliation":[{"name":"Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil"},{"name":"Department of Medical Oncology, Hospital S\u00edrio-Liban\u00eas, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Soares","sequence":"additional","affiliation":[{"name":"Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil"},{"name":"Department of Medical Oncology, Hospital Israelita Albert Einstein, S\u00e3o Paulo, Brazil"},{"name":"Centro Paulista de Oncologia\u2013Oncoclinicas, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio Augusto Barros","family":"Schutz","sequence":"additional","affiliation":[{"name":"Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil"},{"name":"Department of Medical Oncology, Benefic\u00eancia Portuguesa de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Cronemberger","sequence":"additional","affiliation":[{"name":"Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil"},{"name":"Centro Regional Integrado de Oncologia, Fortaleza, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murilo","family":"de Almeida Luz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Erasto Gaertner, Curitiba, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suelen Patricia Dos Santos","family":"Martins","sequence":"additional","affiliation":[{"name":"Centro de Estudos e Pesquisa de Hematologia\u2013Centro Universit\u00e1rio Faculdade de Medicina do ABC (CEPHO-FMABC), Santo Andr\u00e9, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Queiroz Borges","family":"Muniz","sequence":"additional","affiliation":[{"name":"Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo (ICESP), S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio Mavignier","family":"C\u00e1rcano","sequence":"additional","affiliation":[{"name":"Hospital de C\u00e2ncer de Barretos, Barretos, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oren","family":"Smaletz","sequence":"additional","affiliation":[{"name":"Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil"},{"name":"Department of Medical Oncology, Hospital Israelita Albert Einstein, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1bio Affonso","family":"Peixoto","sequence":"additional","affiliation":[{"name":"Instituto COI de Educa\u00e7\u00e3o, Pesquisa e Gest\u00e3o em Sa\u00fade, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Juliana","family":"Gomes","sequence":"additional","affiliation":[{"name":"Liga Norte Riograndense Contra o C\u00e2ncer, Natal, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe Melo","family":"Cruz","sequence":"additional","affiliation":[{"name":"IBCC Oncologia\u2013Centro Universit\u00e1rio S\u00e3o Camilo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1bio Andr\u00e9","family":"Franke","sequence":"additional","affiliation":[{"name":"Oncosite-Centro de Pesquisa Cl\u00ednica, Iju\u00ed, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Herchenhorn","sequence":"additional","affiliation":[{"name":"Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil"},{"name":"Oncologia D\u2019OR\/Instituto D\u2019OR de Ensino e Pesquisa, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemarie","family":"Gidekel","sequence":"additional","affiliation":[{"name":"Now with Janssen Pharmaceuticals, Latin America, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Werutsky","sequence":"additional","affiliation":[{"name":"Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiane Francieli","family":"Rebelatto","sequence":"additional","affiliation":[{"name":"Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaela","family":"Gomes de Jesus","sequence":"additional","affiliation":[{"name":"Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius Carrera","family":"Souza","sequence":"additional","affiliation":[{"name":"Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil"},{"name":"Oncologia D\u2019OR, Salvador, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 Poisl","family":"Fay","sequence":"additional","affiliation":[{"name":"Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil"},{"name":"Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul (PUCRS) School of Medicine, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Cotait","family":"Maluf","sequence":"additional","affiliation":[{"name":"Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil"},{"name":"Department of Medical Oncology, Hospital Israelita Albert Einstein, S\u00e3o Paulo, Brazil"},{"name":"Department of Medical Oncology, Benefic\u00eancia Portuguesa de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"issue":"10305","key":"zoi241520r1","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","article-title":"Prostate cancer.","volume":"398","author":"Sandhu","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"zoi241520r2","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","article-title":"Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.","volume":"30","author":"Clarke","year":"2019","journal-title":"Ann Oncol"},{"issue":"4","key":"zoi241520r3","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy.","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi241520r4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer.","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi241520r5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer.","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"zoi241520r6","doi-asserted-by":"publisher","first-page":"S1300","DOI":"10.1016\/j.annonc.2021.08.2101","article-title":"LBA25 final overall survival (OS) analysis from ARCHES: a phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC).","volume":"32","author":"Armstrong","year":"2021","journal-title":"Ann Oncol"},{"issue":"10336","key":"zoi241520r7","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2?\u00d7?2 factorial design.","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"zoi241520r8","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer.","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi241520r9","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.6004\/jnccn.2012.0115","article-title":"Androgen deprivation therapy: minimizing exposure and mitigating side effects.","volume":"10","author":"Gazta\u00f1aga","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"zoi241520r10","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them.","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur Urol"},{"issue":"4","key":"zoi241520r11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.eururo.2020.03.019","article-title":"Effect of enzalutamide plus androgen deprivation therapy on health-related quality of life in patients with metastatic hormone-sensitive prostate cancer: an analysis of the ARCHES randomised, placebo-controlled, phase 3 study.","volume":"78","author":"Stenzl","year":"2020","journal-title":"Eur Urol"},{"issue":"11","key":"zoi241520r12","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S1470-2045(19)30620-5","article-title":"Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.","volume":"20","author":"Agarwal","year":"2019","journal-title":"Lancet Oncol"},{"key":"zoi241520r13","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2018.08.010","article-title":"Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: a network meta-analysis.","volume":"103","author":"Feyerabend","year":"2018","journal-title":"Eur J Cancer"},{"issue":"4","key":"zoi241520r14","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.euf.2020.01.017","article-title":"Health-related quality of life in patients with advanced prostate cancer: a systematic review.","volume":"7","author":"Kretschmer","year":"2021","journal-title":"Eur Urol Focus"},{"key":"zoi241520r15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejca.2021.08.032","article-title":"A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415).","volume":"158","author":"Maluf","year":"2021","journal-title":"Eur J Cancer"},{"issue":"20","key":"zoi241520r16","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"6","key":"zoi241520r18","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/S0090-4295(97)00459-7","article-title":"Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy\u2013prostate instrument.","volume":"50","author":"Esper","year":"1997","journal-title":"Urology"},{"issue":"3","key":"zoi241520r19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11912-020-0890-3","article-title":"Integration of patient reported outcomes in drug development in genitourinary cancers.","volume":"22","author":"Wong","year":"2020","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"zoi241520r20","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.eururo.2015.06.007","article-title":"Development of a standardized set of patient-centered outcomes for advanced prostate cancer: an international effort for a unified approach.","volume":"68","author":"Morgans","year":"2015","journal-title":"Eur Urol"},{"issue":"2","key":"zoi241520r21","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.euf.2018.12.007","article-title":"Patient-reported outcomes in metastatic castration-sensitive prostate cancer in the adjuvant setting.","volume":"5","author":"Morgans","year":"2019","journal-title":"Eur Urol Focus"},{"issue":"2","key":"zoi241520r22","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S1470-2045(17)30911-7","article-title":"Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.","volume":"19","author":"Chi","year":"2018","journal-title":"Lancet Oncol"},{"key":"zoi241520r23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1200\/JCO.2020.38.6_suppl.14","article-title":"Comparative quality of life in patients randomized contemporaneously to docetaxel or abiraterone in the STAMPEDE trial.","volume":"38","author":"Rush","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi241520r24","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S1470-2045(14)70129-9","article-title":"Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study.","volume":"15","author":"Tombal","year":"2014","journal-title":"Lancet Oncol"},{"key":"zoi241520r25","doi-asserted-by":"publisher","author":"Aggarwal","journal-title":"Prostate Cancer","DOI":"10.1155\/2022\/5454727"},{"issue":"16","key":"zoi241520r26","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer.","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi241520r27","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.euo.2024.01.009","article-title":"A phase 2 randomized open-label study of oral darolutamide monotherapy versus androgen deprivation therapy in men with hormone-sensitive prostate cancer (EORTC-GUCG 1532).","volume":"7","author":"Tombal","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"zoi241520r28","doi-asserted-by":"publisher","first-page":"v886","DOI":"10.1093\/annonc\/mdz394.046","article-title":"Health-related quality of life (HRQL) in a randomized phase III trial of enzalutamide with standard first-line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led, international, co-operative group trial.","volume":"30","author":"Stockler","year":"2019","journal-title":"Ann Oncol"},{"key":"zoi241520r17","unstructured":"Randomize.net. A comprehensive internet-based randomization service for clinical trials. Accessed October 20, 2017. http:\/\/www.randomize.net\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2829074\/bastos_2025_oi_241520_1735839990.79413.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T16:01:27Z","timestamp":1736784087000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2829074"}},"subtitle":["Secondary Analysis of a Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.54253","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]}}}